| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | -559,599 | -811,011 |
| Acquired in-process research and development | 947,862 | 905,362 |
| Intangible asset amortization | 484,919 | 316,551 |
| Share-based compensation | 220,279 | 132,154 |
| Acquisition accounting inventory fair value step-up adjustment | 107,344 | 66,989 |
| Depreciation | 32,209 | 22,331 |
| Non-cash interest expense | 27,213 | 21,914 |
| Provision for losses on accounts receivable and inventory | 14,994 | 6,771 |
| Deferred tax benefit | -381,662 | -110,252 |
| Other non-cash transactions | -8,058 | -7,042 |
| Accounts receivable | 40,466 | -10,530 |
| Inventories | 93,761 | 61,852 |
| Prepaid expenses and other current assets | -1,538 | -8,212 |
| Operating lease assets | -15,618 | -12,440 |
| Other non-current assets | -18,022 | 802 |
| Accounts payable | 68,823 | 6,465 |
| Accrued liabilities | 50,926 | -75,351 |
| Income taxes payable | 72,008 | 59,270 |
| Operating lease liabilities, less current portion | -6,362 | -2,887 |
| Other non-current liabilities | 5,292 | 4,763 |
| Net cash provided by operating activities | 993,255 | 518,639 |
| Acquisition of investments | 1,320,175 | 680,050 |
| Asset acquisition, net of cash acquired | 858,053 | 858,053 |
| Acquisition of intangible assets | 55,000 | 25,000 |
| Acquired in-process research and development | 42,500 | 0 |
| Purchases of property, plant and equipment | 42,023 | 26,848 |
| Proceeds from maturity of investments | 1,180,000 | 780,000 |
| Net cash used in investing activities | -1,137,751 | -809,951 |
| Repayments of long-term debt | 773,250 | 765,500 |
| Share repurchases | 125,023 | 125,023 |
| Payment of employee withholding taxes related to share-based awards | 73,224 | 69,412 |
| Proceeds from employee equity incentive and purchase plans | 22,677 | 21,944 |
| Repayment of 2024 notes | 0 | - |
| Net proceeds from issuance of 2030 notes | 0 | - |
| Net cash provided by (used in) financing activities | -948,820 | -937,991 |
| Effect of exchange rates on cash and cash equivalents | 6,522 | 6,319 |
| Net increase (decrease) in cash and cash equivalents | -1,086,794 | -1,222,984 |
| Cash and cash equivalents at beginning of period | 2,412,864 | - |
| Cash and cash equivalents at end of period | 1,326,070 | - |
Jazz Pharmaceuticals plc (JAZZ)
Jazz Pharmaceuticals plc (JAZZ)